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The desire to improve and expand the scope of clinical magnetic 
resonance imaging (MRI) has prompted the search for contrast agents 
of higher efficiency. The development of better agents requires 
consideration of the fundamental coordination chemistry of the 
gadolinium(III) ion and the parameters that affect its efficacy as a 
proton relaxation agent. In optimizing each parameter, other practical 
issues such as solubility and in vivo toxicity must also be addressed, 
making the attainment of safe, high-relaxivity agents a challenging 
goal. Here we present recent advances in the field, with an emphasis 
on the hydroxypyridinone family of GdIII chelates.
1. Introduction 
Magnetic Resonance Imaging (MRI) has become an important 
technique in modern diagnostic medicine, providing high-quality 
three-dimensional images of soft tissue without the need for harmful 
ionizing radiation.[1] Signal intensity in MRI is related to the 
relaxation rate of in vivo water protons and can be enhanced by the 
administration of a contrast agent prior to scanning. These agents 
utilize paramagnetic metal ions and are evaluated on the basis of 
their ability to increase the relaxation rate of nearby water proton 
spins per concentration of agent administered (i.e. relaxivity). 
Gadolinium(III), with its high magnetic moment and long electron 
spin relaxation time, is an ideal candidate for such a proton 
relaxation agent and is the most widely used metal.[2, 3] Free GdIII, is 
toxic (LD50 of 0.2 mmol/kg in mice)[4] and must therefore be 
administered in the form of stable chelates that will prevent the 
release of the metal ion in vivo. For these reasons, the development 
of ligands for GdIII, suitable for production of high-relaxivity agents 
with favorable properties for imaging applications, remains an 
important goal. 
The purpose of this mini-review is to provide a brief summary 
of changes in the contrast agent field that emphasizes the 
hydroxypyridinone (HOPO) class of compounds developed by our 
research group. Principles governing contrast agent efficacy will be 
discussed with regard to the underlying coordination chemistry of 
the GdIII ion. Highlights will include some of the major conclusions 
drawn from the background of this field and theory relevant to the 
rest of the discussion. For a more detailed account of the theory, the 
reader is referred to several of the excellent reviews on the subject.[1-
3, 5] While not intended to be a comprehensive report, several recent 
attempts to improve agent efficiency through structural modification 
of the commercially used aminocarboxylate ligands are also 
presented. 
1.1. MRI Contrast Agents 
 Paramagnetic contrast agents enhance the contrast in an MR 
image by positively influencing the relaxation rates of water protons 
in the immediate surroundings of the tissue in which they localize.[2, 
6] The first experiments to demonstrate the feasibility of such a 
concept employed manganese(II) salts and achieved tissue 
discrimination in animal studies.[7, 8] Since these early reports, GdIII 
has become the most widely used metal for the production of 
paramagnetic contrast agents. The seven unpaired GdIII electrons 
combined with a relatively long electronic relaxation time make this 
lanthanide effective as a proton relaxation agent. GdIII was utilized 
in the first approved contrast agent in 1988, and while other systems 
based on Fe-oxide particles and Mn(II) have been approved, Gd-
based agents are by far the most commonly used agents in the 
clinic.[2, 5] It is worth noting that while contrast agents containing 
GdIII increase both the longitudinal and transverse relaxation rates, 
the percentage change in tissue is much greater for the longitudinal 
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rate (1/T1). As a result, such agents are best visualized with T1-
weighted scans.[2] 
 The most commonly used commercial contrast agents are 
shown in Figure 1. All such agents utilize polyaminocarboxylate 
ligands which incorporate nitrogen and oxygen donor atoms for the 
GdIII ion. The first six complexes shown in Figure 1 act as 
nonspecific extracellular agents. Following intravascular injection, 
these compounds distribute rapidly between plasma and interstitial 
spaces and are ultimately eliminated via the renal route with half-
lives of about 1.6 hours.[9, 10] The remaining three DTPA derivatives, 
[Gd(EOB-DTPA)(H2O)]2-, MS-325, and [Gd(BOPTA)(H2O)]2-, are 
designed specifically as targeted agents. The BOPTA complex, 
MultiHance, is known to target the hepatobiliary system and acts as 
a liver imaging agent,[2, 11, 12] while MS-325 interacts noncovalently 
with the abundant blood protein Human Serum Albumin (HSA). 
Once bound to HSA, the proton relaxation efficiency of MS-325 
increases and the longer in vivo retention times present opportunities 
for MR angiography.[13-15]  Common to all the aminocarboxylate-
based commercial agents is the octadentate ligand motif, a chelate 
design that leaves only one open coordination site for a single inner-
sphere water molecule. This low hydration number (q) limits the 
potential effectiveness of these complexes as relaxation agents (vide 
infra). 
 
Figure 1. Commercial aminocarboxylate-based MRI contrast agents 
(BSP = Bayer Schering Pharma AG). 
1.2. Relaxivity and S.B.M. Theory 
Contrast agents are evaluated on the basis of their relaxivity, or 
how much the relaxation rates of water protons are increased in the 
presence of the agent at a given concentration. The observed 
relaxation rate of solvent protons, in this case water protons, is 
comprised of both diamagnetic and paramagnetic contributions. The 
paramagnetic contribution is linearly related to the concentration of 
paramagnetic species present. Relaxivity is then defined as the 
increase in relaxation rate per concentration of the paramagnetic 
agent, or the slope of a plot of (1/Ti)obs versus concentration (ri, 
Equation 1).  
(1/Ti)obs = (1/Ti)diamagnetic + ri[Gd]      i = 1, 2      (1) 
Paramagnetic relaxation enhancement includes both an inner-sphere 
component from the proton relaxation of a solvent molecule directly 
coordinated to the GdIII ion, and an outer-sphere component from 
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solvent in the second coordination sphere and the bulk solvent. 
Current agent design focuses mainly on attaining higher inner-
sphere, longitudinal relaxivity, r1p, from protons of water molecules 
in the first coordination sphere of the metal. Equation 2 reveals that 
if water exchange at the GdIII center is fast enough (small values of 
τM, the mean water residence time), the paramagnetic relaxation 
enhancement experienced by the bulk solvent will come from the 
relaxation rate (1/T1m) increase of the coordinated solvent molecule 
(1/T1 is the longitudinal relaxation rate, q is the number of bound 
solvent molecules, and Pm is the mole fraction of water coordinated 
to the metal center). According to the Solomon-Bloembergen-
Morgan (S.B.M.) equations of paramagnetic relaxation theory,[16-20] 
T1m for the applicable dipole-dipole relaxation mechanism is defined 
by Equation 3. This equation shows that modulation of the 
correlation time τc defined in Equation 4 becomes critical in the 
obtainment of the high relaxivities predicted by theory.[2] 
(1/T1) = qPm[1/(T1m + τM)]      (2) 
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1/τci = 1/τR + 1/Tie + 1/τM       i = 1, 2      (4) 
 The relaxivities of current commercial agents based on 
polyaminocarboxylate scaffolds are small compared to what is 
theoretically possible, with r1p values of only 4 - 5 mM-1s-1.[2, 21] As 
shown by equations 2-4, theory demonstrates the need to maximize 
the hydration number q (q = 1 for all commercial agents) and 
optimize τM (150 - 1000 ns in commercial agents), the rotational 
correlation time τR (in the ps regime for small molecules), and the 
electronic relaxation times Tie to obtain high relaxivity. These 
parameters are illustrated pictorially in Figure 2, and their 
optimization can result in a dramatic increase in relaxivity. At 20 
MHz, the relaxivity for a q = 3 complex can theoretically reach 
values of above 300 mM-1s-1, representing a 60-fold increase over 
the relaxivities of current commercial agents. Such high relaxivities 
can only be attained, however, if all relevant parameters are 
optimized. In particular, optimal values of about 1-30 ns for water 
residence times (τM; optimal value decreases with increasing 
magnetic field strength) and ns values of the rotational correlation 
time (τR) are required to reach the peak in the relaxivity profile. It is 
therefore necessary to increase water exchange rates and slow down 
molecular tumbling relative to commercial agents, while also 
maintaining long electronic relaxation times with a high number of 
inner-sphere water molecules to achieve the high relaxivities 
predicted by theory. While attaining a more favorable combination 
of these parameters relative to current agents is desirable, it must 
come without sacrificing chelate stability, so that toxicity due to free 
GdIII is avoided. This clearly presents a challenging problem for the 
coordination chemist! 
     
 
Figure 2. Schematic of selected key factors that affect proton 
relaxivity, r1p. 
1.3. Designing GdIII-based Imaging Agents: A 
Coordination Chemistry Problem 
In addition to the favorable electronic properties mentioned 
above, the general coordination chemistry of the GdIII ion lends 
itself to its application as a relaxation agent; fast water exchange 
rates are crucial for attaining high relaxivity, and the ionic radius of 
GdIII is ideal for fast exchange. Due to lanthanide contraction,[22-25] 
lanthanide sizes decrease across the 4f row of the periodic table, 
resulting in higher coordination numbers for the early lanthanides 
and smaller coordination numbers for those toward the end of the 
series. Since the GdIII ion is situated in the middle of the row, a low 
energy barrier exists between the eight- and nine-coordination states, 
favoring a fluxional state between the two. The rate of water 
exchange of GdIII, once complexed, however, is slowed significantly 
relative to that of the free ion, often to the extent that it is no longer 
in the optimal range for high relaxivity. In addition, there is a 
significant decrease in the number of inner-sphere water molecules 
as they are replaced by ligating atoms in a chelating ligand.  
Related to water exchange, an important trend to consider when 
designing new contrast agents is relaxation dispersion: the inherent 
decrease in proton relaxation rates with increasing magnetic field 
strength.[1, 26, 27] With the appearance of new high field scanners 
(100 MHz and above) in clinics that give better signal-to-noise 
ratios this effect becomes significant. Thus, short water residence 
times (or fast water exchange rates) become increasingly important 
at high field, with the optimal value for τM decreasing to about 1 ns 
for 2.4 T scanners (100 MHz proton Larmor frequency). To attain 
high relaxivities at high fields, the coordination chemistry challenge 
therefore involves the design of ligands that effectively chelate GdIII 
while limiting the decrease in the water exchange rate and reduction 
in q once the ion is bound. 
2. Recent Strategies in Contrast Agent Design 
The primary developmental focus of next-generation MRI 
contrast agents has been the synthesis of derivatives of the 
aminocarboxylate systems used in the clinic. Features of compounds 
such as DTPA and DOTA include inexpensive streamlined 
syntheses, as well as adequate solubility and toxicological 
parameters.[1, 28, 29] The following examples illustrate several 
approaches toward optimizing the aminocarboxylate system en route 
to more efficient relaxation agents. 
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Research efforts in new contrast agent design are generally 
directed towards the optimization of one or more of the 
aforementioned relaxation parameters through ligand structural 
modification. For example, Merbach and coworkers have reported 
numerous studies that probe the factors influencing the water 
exchange rate of aminocarboxylate GdIII complexes.[30-34] The main 
explanation for increased water exchange rates is steric crowding at 
the water binding sites, a property that favors the release of the 
coordinated water molecule in a dissociative exchange process. 
Derivatives of DTPA, shown in Figure 3, have been synthesized 
with varying numbers of carbon atoms in the ligand scaffold. As 
shown by the τM values, water exchange is accelerated in the 
resultant GdIII complexes with values approaching the optimal range 
for high relaxivity at higher magnetic fields (60 – 100 MHz). This 
rate enhancement is achieved, however, at the cost of 
thermodynamic stability, as measured by the relatively low pGd[35] 
values (Figure 3). This phenomenon of decreased stability upon 
increasing water exchange is common for aminocarboxylate ligands 
and must be addressed when considering these complexes as high-
relaxivity agents, particularly at the high magnetic field strengths of 
future clinical scanners. 
 
Figure 3. The DTPA ligand and two of its representative derivatives 
prepared for water exchange rate studies.[31, 32] 
 Increased water exchange rates for macrocyclic complexes 
based on [Gd-DOTA(H2O)]- (Figure 1) have also been reported. The 
pyridine-N-oxide derivative of DOTA (Figure 4) resulted in a Gd 
complex with a significantly faster water exchange rate than the 
parent complex (τM of 39 versus 244 ns.[36] ). As with the linear 
aminocarboxylates mentioned previously, the rate acceleration was 
attributed to an increase in steric crowding. A monophosphinic acid 
derivative (Figure 4) was found to possess a faster exchange rate 
than the parent DOTA complex with a τM of 16.[37] Steric crowding 
due to the bulky phosphinate group is given as a rationale for the 
increased rate in addition to a possible favorable arrangement of 
water molecules in a second coordination sphere. The relaxivity of 
this complex is 6 mM-1s-1 (20 MHz, 25 °C), an improvement over 
commercial agents. 
 
Figure 4. The DOTA ligand and representative derivatives prepared 
to increase water exchange rates.[36, 37] 
Complexes with higher q values have also been reported for 
aminocarboxylate systems in efforts to achieve higher relaxivity. As 
indicated by Equation 2, relaxivity is highly dependent on this 
parameter, and relaxivity values will always be limited for 
complexes that possess only one coordinated water (q = 1). Two 
examples of q = 2 complexes are depicted in Figure 5. In each case, 
DTPA complexes are tethered to a central core to produce dinuclear 
GdIII complexes with increased hydration numbers 
(q = 2). The relaxivity values of [Gd2(pX(DTTA)2)(H2O)4]2- and 
[Gd2(mX(DTTA)2)(H2O)4]2- are 12.8 and 11.6 mM-1s-1 (20 MHz, 37 
°C), respectively, and represent significant increases over that of the 
parent DTPA complex (r1p = 4.3 mM-1s-1).[2] These values are 
influenced by the higher q value and (due to increased molecular 
weight) by an increase in the rotational correlation time, τR.[38] A 
supramolecular approach was used to generate another dinuclear q = 
2 complex via Fe-terpyridine complexes derivatized with DTPA 
(Figure 5). The high relaxivity of [Fe(tpy-DTTA)2Gd2(H2O)4] (15.7 
mM-1s-1, 20 MHz, 37 °C) is attributed to an increase in q as well as a 
long τR value resulting from the higher molecular weight and 
rigidity of the complex.[39] 
 
Figure 5. Examples of dinuclear, q = 2 DTPA-based GdIII complexes 
proposed as improved high-relaxivity MRI contrast agents.[38, 39] 
While the relaxometric properties of such q = 2 compounds are 
improved, the thermodynamic chelate stability suffers greatly in 
both cases. The increase in q (Figure 5) from one to two is made 
possible by removing one carboxylate arm of the parent DTPA to 
open up a metal coordination site. As is observed in accelerating 
water exchange in the aminocarboxylate class of compounds, 
attaining a higher number of coordinated water molecules by 
decreasing ligand denticity is accompanied by a dramatic decrease 
in thermodynamic stability. The pGd values for the p- and m-
substituted xylene-based complexes, 16.2 and 15.1, respectively, are 
significantly lower than the value of 19.1 for the parent DTPA 
complex.[28] Even less stable is the Fe-terpyridine complex; its pGd 
value of 10.6 represents more than a 5 log unit decrease in stability 
relative to DTPA-BMA (pGd = 15.8) (Figure 1), the ligand with the 
lowest pGd value of all clinically approved agents. This effect of 
decreased stability upon increasing q or water exchange rates raises 
a key concern in contrast agent design: The optimization of one 
parameter will often hamper that of another, making the goal of 
high-relaxivity, practical agents a major challenge. To achieve a 
practical high-relaxivity agent, the optimal combination of all 
relevant parameters must be accomplished while maintaining 
solubility and chelate stability. 
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As an example of a Gd-based contrast agent not focused on 
traditional aminocarboxylate ligand scaffolds, Wilson and 
coworkers have reported several studies of GdIII encapsulated inside 
fullerene cages.[40-42] The peripheries of these cages are decorated 
with solubilizing groups to allow for application of C60 in aqueous 
media. Relaxivities ranging from about 10 to as high as 38.5 mM-1s-
1 (30 MHz, 26 °C) are due entirely to second and outer-sphere 
relaxation, as there are no inner-sphere waters directly coordinated 
to the Gd. In solution, these “gadofullerenes” aggregate, resulting in 
large assemblies with long rotational correlation times and 
consequent high relaxivities.[42] However, practical concerns such as 
in vivo toxicity and deaggregation in the presence of various salts 
(thereby limiting the effect of long τR values on relaxivity)[43] may 
preclude considering such systems for contrast agent applications. 
 
3. Hydroxypyridinone-based agents 
In 1995, Raymond and coworkers reported a GdIII complex that 
showed promise as a contrast agent, Gd-TREN-1-Me-3,2-HOPO (1, 
Figure 6).[44] The X-ray crystal structure revealed that the TREN 
(tris-(2-aminoethyl)-amine) capped tripodal hydroxypyridinone 
(HOPO) ligand is hexadentate, leaving two open water coordination 
sites in its overall 8-coordinate complex. The r1p value of this 
complex, 10.5 mM-1s-1 (20 MHz, 37˚C), is more than twice that of 
commercial agents. This observed increase is due in large part to a q 
value of 2, a quantity double that of current commercial agents, 
combined with a rapid water exchange rate. Even more important 
and unlike that of previous q = 2 complexes, the stability of this 
complex is higher than that of commercial agents despite the lower 
ligand denticity (pGd = 19.2[45]). This can be attributed in part to the 
exclusively oxygen donor set provided by the HOPO chelates 
(instead of the mixed oxygen/nitrogen donors of the 
aminocarboxylates) since lanthanide cations prefer hard, anionic 
oxygen donors to nitrogen. 
Since this initial report, a family of HOPO-based Gd complexes 
has been developed to explore the potential of this motif as MRI 
contrast agents.[46] Early studies were hindered by the low aqueous 
solubility of the parent TREN-1-Me-3,2-HOPO complex,[47, 48] 
which led to subsequent effort to improve this important parameter. 
The bis-HOPO-TAM motif (replacement of one HOPO unit with a 
terephthalamide (TAM) chelator) was introduced (2, Figure 6)  to 
create a negatively-charged GdIII complex.[47] A key feature of this 
ligand design is the second amide functionality of the TAM that 
allows for further derivatization with solubilizing and targeting 
groups.[49, 50] Relaxivities of Gd-HOPO and bis-HOPO-TAM 
complexes are generally in the range of 7 – 13 mM-1s-1 (20 MHz), 
and high complex stabilities combined with increased q and optimal 
water exchange rates make these compounds promising as safe, 
high-relaxivity agents at high field. The coordination chemistry and 
relaxometric properties of this class of compounds will be described 
in the following sections with emphasis on recent  work published 
subsequent to a previous review.[46] Additionally, a detailed 
summary of the solution thermodynamic stability and selectivity 
data collected thus far is presented for this class of potential MRI 
contrast agents. 
3.1. Solution Thermodynamics 
High stability is essential for gadolinium chelate complexes 
used in medicine due to toxicity related to the presence of free GdIII 
in vivo. For example, precipitation of the metal can occur in tissue, 
and hydrated lanthanide ions are known to block Ca2+ binding 
sites.[28] When one considers other potential interactions with 
various serum proteins, as well as irreversible binding to skeletal 
tissue that can occur with free GdIII,[2] the importance of the chelate 
staying intact while in the body becomes clear. Utilizing the known 
oxophilicity of lanthanides, purely oxygen donor ligands such as 
hydroxypyridinone (both the 3,2-HOPO and 1,2-HOPO isomers), 
maltol (MAM), and terephthalamide (TAM) have been developed 
and explored as chelators expected to form stable Gd complexes. 
The obtained complexes (with two[46] or three[51] inner-sphere water 
molecules) have been examined as candidates for next generation 
agents. The feasibility of applying these O donor ligands as practical 
agents has been proven successfully in vivo.[52] Scaffold and chelate 
group variations were also examined to help understand the 
principles governing stability aspects. The results obtained from 
these solution thermodynamic studies are summarized in the 
following sections. 
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Figure 6. Chemical structures of HOPO-based GdIII complexes discussed in this paper. 
 
Stability Constants 
Thermodynamic stability data of HOPO-based chelates have 
been published. Typically, stabilities of MRI contrast agents are 
reported as their pGd values, thus providing a convenient way to 
compare stabilities of chelates with differing protonation behavior.[2, 
53] These pGd values range from 13.7 to 20.6 (see Table 1) for 
hexadentate ligands, and one octadentate ligand achieves a pGd 21.2. 
For comparison, the benchmark compounds DTPA and DOTA 
reach 19.1[2, 28] and 20.4,[54] respectively, while DTPA-BMA has the 
lowest value of all approved agents at 15.8. 
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Figure 7. Metal binding constants for GdIII, ZnII, and CaII versus ligand 
acidity of a series of TREN ligands (Table 1, entries 1 through 10 for 
GdIII). The symbols of diamonds, squares, and triangles correspond to 
binding constants for Gd, Zn, and Ca, respectively. 
The favorable thermodynamic properties of HOPO ligands can 
be attributed to several effects. First, the GdIII cation is highly 
oxophilic and will bind more strongly to the six oxygen donors of 
the HOPO-based ligands than the mixture of nitrogen and oxygen 
donors offered by hexadentate aminocarboxylate ligands. Second, 
the two donor atoms on each HOPO moiety are predisposed to bind 
GdIII in a five-membered chelate ring. Such an arrangement of donor 
atoms is expected to favor larger cations such as CaII or GdIII over 
smaller cations such as ZnII and CuII.[55-57] The final important effect 
is that the Lewis basicities of the HOPO oxygen donor atoms are an 
optimal match for GdIII, resulting in strong binding.[45, 55, 56] 
 Scaffold 
A significant factor in chelate stability is the ligand cap scaffold. 
The TREN scaffold has been found to provide the highest chelate 
stability for hexadentate HOPO ligands. For example, in a series of 
1-Me-3,2-HOPO ligands, replacing TREN[45] with the propylene-
bridged cap TRPN (12),[58] extending TREN via insertion of three 
Gly spacers into the ligand arms (11),[58] or variation towards a more 
sterically crowded Ser-TREN (9)[59] reduces pGd from 19.2 to 16.7, 
15.6, and 17.7, respectively. Complex 12 demonstrates the 
importance of an intramolecular hydrogen-bonding network which 
preorganizes the ligand for metal complexation in the TREN-capped 
complexes such as 1.[44, 60, 61] The extension of the spacer in TRPN 
disrupts these interactions, resulting in a lower pGd. While most 
deviations from the TREN cap have resulted in significantly 
decreased stability, an exception is the TACN (triazacyclononane) 
scaffold (13) which attains a similar pGd = 18.7.[51] 
Table 1. Ligand acidity, GdIII binding constants logβ110 (in 0.1 M KCl at 
298 K) and pGd values of various HOPO-based chelate systems. The 
top section summarizes TREN capped ligands, and the remaining 
ligands are listed at the bottom. 
Σ pKa logβ110  pGd[b] Compound (number from 
Figure 6) 
Ref 
20.70 18.5 19.3 TREN-1,2-HOPO (3) 69 
21.90[a] 18.5[a] 19.3[a] TREN-MAM (6) 63 
24.15[a] 18.7[a] 19.0[a] TREN-Me-MAM (7) 63 
25.69 19.7 19.8 TREN-1-MOE-3,2-HOPO 48 
(4) 
25.96 19.2 19.2 
TREN-1-Me-3,2-HOPO 
(1) 45 
27.57 18.2 18.0 TREN-5,4-HOPY (5) 67 
27.61 20.3 19.5 
TREN-6-Me-3,2-HOPO 
(8) 45 
37.34 24.1 20.1 
TREN-bis-1-Me-3,2-
HOPO-TAM-Me (2) 47 
38.05 24.3 20.3 
TREN-bis-1-Me-3,2-
HOPO-TAM-EA (20) 66 
38.64 24.9 20.6 
TREN-bis-6-Me-3,2-
HOPO-TAM-PEG3Et (16) 62 
24.52 15.9 16.7 
TREN-Gly-3,2-HOPO 
(11) 58 
24.77 17.2 17.7 Ser-TREN-3,2-HOPO (9) 59 
26.59 16.5 16.2 
TREN-bis-3,2-HOPO-
IAM (17) 47 
26.59 14.8 13.7 
TREN-bis-3,2-HOPO-
BAC (18) 47 
27.53 16.5 15.6 
TRPN-1-Me-3,2-HOPO 
(12) 58 
28.13 17.3 16.1 
TREN-bis-3,2-HOPO-
SAM (15) 47 
37.11 21.5 21.2 H(2,2)-1,2-HOPO (19) 65 
[a] 0.1 N NaCl [b] pH = 7.4; cMtot = 1 µM; cLtot = 10 µM. 
Acidity 
Variations in the chelate groups influence pGd values only to a 
minor extent in the examined TREN-capped hexadentate, 
homopodal ligands. TREN-3,2-HOPO (1), TREN-MAM (6), 
TREN-1,2-HOPO (3), TREN-1-MOE-3,2-HOPO (4), and TREN-6-
Me-3,2-HOPO (8) all have similar pGd values falling in the range of 
19.2 – 19.8, values that slightly exceed the benchmark compound 
Gd-DTPA (19.1). The only notable exception is TREN-5,4-HOPY 
(5), with a lower pGd of 18.0. Significant differences across the 
series appear more clearly, however, when considering log β values 
and protonation constants for a series of TREN-HOPO based 
complexes (Table 1 and Figure 7). The log β values for GdIII 
binding increase with the increasing ligand basicity for the series.  
The pGd value varies with pH and a plot of pGd versus pH can 
indicate the acid resistance of the GdIII complex (Figure 8). The 
more acidic TREN-1,2-HOPO ligand has greater resistance to acid 
hydrolysis, when compared to Gd-DTPA. In comparison, the more 
basic TREN-3,2-HOPO ligand forms a Gd complex that is more 
acid-sensitive than both DTPA and Gd-TREN-1,2-HOPO. The 
variation of pGd with pH for a particular GdIII complex can thus 
give useful information about the stability of the complex under 
different pH conditions in vivo. In considering targeted imaging, 
such information can serve as an important guide when designing 
agents for a specific region of a particular pH.  
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Figure 8. Ligand acidity influences the acid resistance of the complex. 
Basic 1-Me-3,2-HOPO chelates tend to be slightly more sensitive to 
acid than DTPA, while acidic 1,2-HOPO and MAM ligands form more 
stable GdIII complexes under acidic conditions than DTPA. 
 
Charge 
The influence of the overall charge of the GdIII complex on the 
stability constant pGd is demonstrated in a series of eight TREN-
bis-3,2-HOPO-TAM chelates (23 – 30). Varying the substituent on 
the TAM moiety and consequently the complex charge resulted in 
pGd values ranging from 17.1 (-3 charge) to 19.9 (neutral).[64] 
Interestingly, the three anionic complexes of –1 charge (23, 25 and 
30) all exhibit the same pGd value. This study demonstrated that, to 
maximize stability, the charge of the complex should be as close to 
zero as possible, with the highest pGd belonging to the neutral 
amine substituted complex 26. 
Selectivity 
For CaII and ZnII binding, no clear trend between ligand acidity 
and binding strength is seen in the data shown in Figure 7. The more 
basic ligands have a higher selectivity for GdIII over ZnII and CaII, as 
indicated by the differences in the pM values illustrated in the 
following examples. The two more basic TREN-bis3,2-HOPO-TAM 
ligands (20 and 25) prefer GdIII by Δp(Gd-Zn) = 8.1 and 7.0,[64, 66, 68] 
while the relatively less basic TREN-1-Me-3,2-HOPO (1) achieves 
a selectivity of Δp(Gd-Zn) = 6.1,[44, 45] all of which exceed that of 
DTPA (Δp(Gd-Zn) = 4.2). The GdIII selectivity of the most acidic 
ligand, TREN-1,2-HOPO (3), is the lowest (Δp(Gd-Zn) = 4.1) 
among the ligands studied.[69] Increasing denticity from six to eight 
improves the discrimination behavior for 1,2-HOPO to Δp(Gd-Zn) = 
6.7 in the case of H(2,2)-1,2-HOPO (19).[65]  
 
Solution Anion Affinity 
Solution serum anion affinities of an anionic (25) and a cationic 
(27) TREN-bis-1-Me-3,2-HOPO-TAM complex (q = 2) are 
comparable to commercial contrast agents (q = 1).[64] Phosphate 
binds weakly with logKA = 1.4 and 2.4, respectively. Oxalate is the 
only other physiologically relevant anion that interacts (logKA = 1.0 
and 2.9) with these complexes. These affinities are similar to the 
phosphate binding values of the commercial contrast agents DTPA 
(logKA = 2.0) and DOTA (logKA = 2.2), while aminocarboxylate 
ligands with q = 2 such as DO3A exhibit higher anion affinities 
(logKA = 4.8).[6] In comparing the HOPO complexes with DO3A, 
this difference in anion binding despite the same hydration number 
(q = 2) illustrates the importance of coordination geometry. In the 
case of 25 and 27, it is proposed that the water molecules are in 
positions anti with respect to one another, making it more difficult to 
displace both waters. Interestingly, the oxalate binding for the 
cationic chelate 27 increased the coordination number from eight to 
nine, but no change in coordination number occurred for the anionic 
chelate 25 since the oxalate replaces both bound water molecules.[64] 
Neutral TREN-1,2-HOPO (3), which contains the more acidic 
chelate 1,2-HOPO, exhibits a small affinity for oxalate (logKA = 
1.5) and an interaction with a bidentate 3,2-HOPO anion could be 
detected (logKA = 3.5) For both the oxalate and bidentate 3,2-HOPO  
anions, an increase in coordination number was observed by 
relaxivity and, in the case of oxalate, by luminescence 
measurements of the Eu(III) analog. No phosphate binding, however, 
could be detected for this ligand.[69] Octadentate H(2,2)-1,2-HOPO 
(19) does not show any anion binding at neutral pH in which the 
neutral, monoprotonated complex GdLH complex dominates.[65] 
Thus, the HOPO-based ligands examined do not have any 
appreciable anion binding for the physiologically relevant anions 
that could affect the in vivo performance of these ligands. 
In Vivo Behavior  
The biodistribution of several of the HOPO-based chelates was 
tested in mice.[52] Depending on the functionalizing groups of the 
chelates, different accumulation locations and finely tuned retention 
times were observed. For example, liver uptake is enhanced upon 
addition of a short polyethylene glycol (PEG) chain to the chelate, 
while longer PEG chains favor blood pool localization. Complex 22, 
bearing a relatively long chain of 123 ether units, gave the best MR 
angiographic results despite the known decrease in human serum 
albumin (HSA) affinity with increasing PEG chain length.[50] In this 
case, the low albumin affinity may enhance the MR angiogram 
quality by limiting water displacement from the Gd center by the 
protein. 
3.2. Tuning q and water exchange 
As most HOPO-based GdIII complexes are 8-coordinate, an 
associative water exchange mechanism involving a 9-coordinate 
intermediate species can be predicted. The energy difference 
between the 8-coordinate ground state and a 9-coordinate 
intermediate is small, leading to fast water exchange and subsequent 
high relaxivity (Figure 9).[62, 70] This rapid exchange rate was 
initially supported by temperature-dependent relaxivity studies and 
the X-ray crystal structure of the La-TREN-1-Me-3,2-HOPO 
complex. In this structure both an 8- and a 9-coordinate metal center 
are observed.[47] The presence of both coordination numbers 
indicates that the coordination environments of the two lanthanide 
ions must be similar in energy and that the ligand motif can 
accommodate both. Indeed, variable pressure 17O NMR studies have 
been carried out for Gd-TREN-bis-6-Me-3,2-HOPO-TAM-TRI (16) 
to determine  a small, negative value for the volume of activation, a 
result indicative of associative interchange exchange.[62] 
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Figure 9. Top: coordination polyhedra of the Gd ion illustrating 
associative water exchange for HOPO-based complexes. Bottom: 
free energy diagrams for water exchange.[47] Most HOPO complexes 
have an 8-coordinate ground state and a 9-coordinate intermediate 
(left) but studies indicate both states are close in energy. 
Since the eight- and nine-coordinate states are close in energy 
for Gd-HOPO complexes, small changes in the ligand structure can 
affect the number of bound water molecules (q) and the rate of water 
exchange. Importantly, increases in q of HOPO-based complexes 
have been accomplished without reducing the denticity of the ligand, 
resulting in complexes with fast water exchange rates that maintain 
the favorable thermodynamic stability properties of the parent 
compound. The following section reviews several examples that 
demonstrate the effect of both ligand scaffold and substituent on 
water coordination in the HOPO family of GdIII complexes. 
Effect of PEG Substituents 
Utilization of the TREN-bis-HOPO-TAM motif as in complex 2 
affords negatively charged Gd complexes and a modest increase in 
aqueous solubility relative to the parent complex 1. In order to 
further enhance solubility of HOPO-based complexes, polyethylene 
glycol (PEG) chains were introduced to the bis-HOPO-TAM design. 
Additionally, it was proposed that the PEG moiety may induce 
noncovalent interactions with the abundant blood protein HSA to 
slow tumbling (higher τR) and thereby increase relaxivity.[49] The 
first PEGs chosen for attachment were chains of 44 (21) and 123 
(22) ether moieties. Analysis of the NMRD profiles of complexes 21 
and 22 indicate a reduction in q relative to the parent q = 2 complex 
2, with the best refinements obtained by fixing q to a value of 1. 
This can be explained by the ether oxygen atoms partially 
coordinating to the Gd center, displacing bound water molecules. 
Variable temperature 17O NMR experiments were conducted to 
yield the water exchange rates of each complex. It was noted that τM 
increases as the PEG chain is lengthened, enabling tuning of the rate. 
A reduction in the hydration number for PEG-substituted complexes 
has also been observed in subsequent studies.[50] While complexes 
bearing chains of 11 and 12 ether units (23) exhibit relaxometric 
behaviour that suggests q = 1,[50, 64] q remains 2 as in the parent 
compound when the chain is reduced to 4 ethers (25). These results 
indicate that a relatively short PEG chain is necessary to balance a 
high q value with water solubility. 
Effect of non-PEG Solubilizing Substituents 
In addition to the PEG-substituted compounds, bis-HOPO-TAM 
complexes bearing alcohols, acids, and amines have been studied 
with regard to their effects on water coordination. In a recent study, 
tuning of the coordination number was demonstrated by the addition 
of pendant amine groups. At physiological pH, one such substituent 
forms a hydrogen bond interaction with a water molecule, thereby 
favoring its coordination (Figure 10). This results in a stabilization 
of the nine-coordinate, q = 3, state in the exchange process, and a 
consequent higher relaxivity (11.1 mM-1s-1; 20 MHz, 298 K, pH 
7).[70] Importantly, the complex (30) retains high stability as 
indicated by the pGd value of 19.4, comparable to [Gd(DTPA)]2-, as 
well as high relaxivity at the relevant magnetic field strengths above 
0.5 T. 
 
 
Figure 10. TREN-bis-HOPO-TAM complexes (27 and 30) substituted 
with pendant amines. The complex (30) shown on the right possesses 
a substituent capable of forming a hydrogen bond with an additional 
water molecule to promote its coordination to the GdIII center. 
Further study of other solubilizing substituents demonstrated the 
abilities of other structures to partake in similar hydrogen bond 
interactions to aid in water binding at the metal center. Complexes 
bearing the ethanolamine moiety (20) and various carboxylic acid 
groups (28 and 29) also have relaxometric properties consistent with 
three bound water molecules as indicated by NMRD profiles.[64] In 
all cases, thermodynamic stabilities were determined to be sufficient 
for consideration of such compounds as clinical agents. Also 
noteworthy is that the water molecule residence times obtained for 
the series of complexes are all similarly short, regardless of complex 
charges or ground state coordination numbers. This observation 
provides further support for the closeness in energy of the eight- and 
nine-coordination states for HOPO-based complexes and reveals 
how subtle changes in ligand structure can alter the nature of the 
ground state (Figure 9). 
TACN-capped Complexes 
The effect of the ligand-capping structure on water coordination 
has also been explored. In a recent report, triazacyclononane 
(TACN) was used as a ligand cap to produce both tris-3,2- and 1,2-
HOPO complexes (13 and 14).[51] Molecular modelling studies 
predicted that the larger cap (relative to TREN) would accommodate 
three inner-sphere water molecules, and subsequent relaxometric 
and luminescent characterization revealed a successful design 
strategy. Relaxivities were found to be 13.1 and 12.5 mM-1s-1 (20 
MHz, 298 K, pH 7), values that remained high at field strengths 
above 0.5 T. The stabilization of the q = 3 complex in this case is 
accomplished without the need for the asymmetric bis-HOPO-TAM 
motif. Use of the TACN cap also results in a dramatic increase in 
aqueous solubility, possibly due in part to protonation of the TACN 
cap resulting in a charged species near neutral pH. Furthermore, 
stability is not significantly affected (pGd = 18.7) upon increasing 
the hydration number to q = 3. These TACN-capped complexes are 
therefore unique examples of highly soluble tris-HOPO GdIII 
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complexes that demonstrate high hydration numbers, fast water 
exchange rates, and high stabilities. 
3.3. Increasing rotational correlation times through 
macromolecular association 
Once the basic hydration and water exchange properties of the 
Gd chelate are optimized, further enhancement of the relaxivity can 
be achieved by grafting the complex to macromolecules to slow 
molecular tumbling, thereby increasing τR. The attachment of 
current commercially available contrast agents such as 
[Gd(DOTA)]2- and [Gd(DTPA)]2- to macromolecular constructs has 
been extensively studied, and in several cases, enhancements have 
been observed upon slowing of molecular rotation.[71-79] These 
contrast agents, however, are somewhat restricted because they do 
not have the optimal water-exchange rates that would lead to large 
enhancements in relaxivity. The major advantage of these 
aminocarboxylate-based contrast agents is their high water-
solubility. For example, in the case of the attachment of multiple 
contrast agents to dendrimers, the solubility of the resulting 
macromolecule would decrease if the contrast agent has low 
solubility. As stated previously, solubility has generally been 
acknowledged as the major drawback in HOPO-based contrast 
agents.[64] While the choice of ligand scaffold can play a role (see 
section 3.2), poor solubility can be alleviated by the use of a more 
soluble macromolecule or by attaching the contrast agent to the 
interior of a soluble macromolecular vehicle. 
Covalent attachment to macromolecules such as dendrimers, 
proteins, virus capsids, and inorganic nanoparticles, encapsulation 
into fullerenes, virus capsids and liposomes, non-covalent 
interactions with proteins, and supramolecular self assembly to form 
larger constructs are ideas that have been explored to build high 
molecular weight contrast agents.[5, 80, 81] Construction of 
macromolecular entities with multiple contrast agents has the 
advantage of increased ionic (per mM Gd) and molecular (per 
particle) relaxivity. The ionic relaxivity increase is due to slower 
molecular tumbling, and the use of multiple attachment sites leads to 
high molecular relaxivities. Macromolecular agents of size greater 
than 10 nm also have potential for application as MR angiography 
agents. These nano-sized particles will preferentially accumulate 
near lesions in vessels, but will not cross the normal healthy 
endothelial layer.[82] The design of macromolecules with different 
attachment sites for contrast agents and targeting agents is the 
ultimate goal in terms of imaging biological targets limited by low 
in vivo concentrations and requiring greater contrast enhancement 
for visualization. High-relaxivity contrast agents based on HOPO 
can theoretically (according to S.B.M. theory) reach the relaxivity 
values (up to 100 mM-1s-1) useful for targeted imaging and are 
therefore excellent candidates for attachment to macromolecules. 
The remainder of this section is devoted to a few representative case 
studies involving the construction of macromolecular HOPO-based 
contrast agents and their comparison to commercial contrast agents. 
HSA binding  
 Non-covalent binding of contrast agents to HSA protein in 
vivo has been used to obtain contrast enhancements. The 
commercial agent Vasovist® (MS-325) is based on this strategy.[71, 76, 
79] Binding of this contrast agent to HSA increases its circulation 
time in blood and also slows down its tumbling rate, leading to 
greater contrast enhancements useful for blood vessel imaging. The 
advantage of this concept is that less material has to be injected into 
the patient, while the concern is the thermodynamic stability of the 
complex (i.e. the agent remains longer in the body depending on the 
binding constant between the agent and HSA). 
 As illustrated in the previous sections (Figure 6) heteropodal 
bis-HOPO-TAM ligands can be modified by the attachment of 
various functional groups via the terminal carboxyl group of the 
TAM moiety. The increase in relaxivity observed for 22 (9.1 mM-1s-
1 from 8.8 mM-1s-1 at 20 MHz) upon the attachment of the PEG 
group is modest considering the large increase in molecular weight, 
both due to the decrease in q and the rapid local motions in the PEG 
chains. The HSA-adduct of 22 afforded a relaxivity of 74 ± 14 mM-
1s-1 at 20 MHz with a formation constant of 186 ± 50 M-1, indicating 
weak binding which leads to a mixture of HSA-bound and unbound 
species.[49] Upon attachment of a benzyl group via the HOPO 
nitrogen atom (10), the HSA binding affinity increased to as high as 
8640 ± 2000 M-1.[50] The number of inner sphere water molecules 
however, is lowered to about zero (due to closer interaction with the 
protein), and results in relaxivities in the range of 15-19 mM-1-s-1. 
For comparison, the association constant of HSA with MS-325 is 
6100 ± 2130 M-1 , and the relaxivity is 50 mM-1s-1 at 25 MHz.[76] 
The interactions between HSA and the hydroxypyridonate 
complexes need further refinement while maintaining high q values 
and limiting rapid local motion. 
 
Figure 11. Supramolecular La based (31) ([La(acac)3/DMSO; the 
coordinated DMSO molecules are omitted for clarity) and FeGd2-
based (32) constructs. 
Fe/Gd supramolecular complexes 
 Self-assembly to supramolecular constructs that contain more 
than one Gd center can lead to high relaxivity agents due to the 
slower tumbling rate of the large construct. This supramolecular 
approach has not yielded a candidate for marketing as a practical 
MRI-contrast agent, however, due to difficulties in synthesis, 
characterization and tailoring final physiological properties of 
defined supramolecular Gd compounds. Many of this class of 
compounds also do not fulfill stability requirements because of 
modifications at the Gd chelating unit. 
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 Supramolecular lanthanide complexes have been reviewed by 
Bünzli and Piguet.[83] For supramolecular d-block metals, the 
concept of “incommensurate coordination number” was 
developed,[84-88] a term that relates to preferred coordination 
geometries of metal centers and rigid ligands with a defined angle 
between chelating groups. Lanthanides are more flexible with regard 
to preferred coordination geometries than transition metals, 
properties that are especially important for Gd-based MRI contrast 
agents (which are at the border of favoring eight or nine coordinate 
geometries, as discussed above). The concept of incommensurate 
coordination number can thus not be transferred directly to 
lanthanides. Nevertheless it has been demonstrated that ligands 
designed along this concept can assemble into supramolecular 
lanthanide complexes. In most cases, the structure of those 
supramolecular assemblies cannot be predicted. The dominant 
example is the “Lord of the Rings” (31).[89] The La8L8 complex 
forms, however, instead of the analogous tetrahedron In6L6 (Figure 
11). Eight lanthanum atoms occupy the eight vertices of the 
polyhedron, while each ligand occupies one of the eight triangular 
faces. Each lanthanum atom is coordinated to three ligands and each 
ligand binds three lanthanum atoms. 
 Most supramolecular constructs developed as potential MRI 
contrast agents are based on attaching preformed GdIII chelates onto 
tris-bidentate Fe(III) complexes. These complexes, commonly 
referred to as 'metallostars', can provide high relaxivity 
enhancements due to molecular weight increases. For example, the 
TTAHA (N-bis(2-aminoethyl)amine-N’,N’,N’’,N’’-tetraacetate) 
based metallostar has a relaxivity of 32 mM-1s-1 at 20 MHz.[90] To 
test the approach of true self-assembly, HOPO-TAM mixed ligands 
have been investigated, using a C3 linker between the TAM 
(terephthalamide) and the HOPO chelates (32, Figure 11).[68] The 
assembly reduces the tumbling of the incorporated Gd-complexes in 
solution, and the resulting longer rotational correlation time afforded 
higher relaxivities of 18.7 mM-1 s-1 and 23 mM-1 s-1 at 20 and 60 
MHz respectively.  
Attachment to dendrimers and virus capsids 
 Covalent attachment of contrast agents to dendrimers has been 
widely explored because of the advantages presented by multiple 
attachments and the deceleration of the tumbling rate due to 
molecular weight enhancement. The important restriction is that the 
molecule has to be rigid enough to prevent vibrational modes that 
allow for fast tumbling of the gadolinium containing portions.[91] 
Gadomer-17, a dendrimer-based contrast agent being developed by 
Schering, affords a 3.5 fold increase in relaxivity relative to the 
starting complex [Gd(DOTA)(H2O)]- (16.5 mM-1s-1 from 4.7 mM-1s-
1 at 20 MHz).[91] The relaxivity enhancement, however, is not as 
high as would be expected for the huge increase in molecular weight 
(40,000 Da) due to a slow water exchange rate. A single molecule of 
Gd-TREN-bis-HOPO-TAM-based complex grafted onto an 
aspartate based dendrimer (33, Figure 12, molecular weight 1576 
g/mol,) gave a relaxivity enhancement of 1.6 times that of Gd-
TREN-bis-HOPO-TAM-Me (2) (14.3 mM-1s-1 from 8.8 mM-1s-1 at 
20 MHz). The compactness of the system and an optimal water-
exchange rate allows reasonable relaxivity enhancements, despite 
the fact that the molecular weight increase is not as large.[92] 
Virus capsids have recently been explored as potential scaffolds 
for attachment of Gd-chelates.[73, 77, 81, 93] Covalent attachment of 
TREN-bis-HOPO-TAM-based chelates onto bacteriophage MS2 
capsids (90 chelates per capsid) has led to one of the highest 
relaxivities yet reported for these systems (Figure 12).[94] The capsid 
shell consists of 180 copies of the coat protein (relative molecular 
mass (Mr) 13,700) assembled into an icosahedral arrangement 
(Figure 12). The diameter of this nanosized assembly is 27.4 nm, 
and its surfaces can be modified through lysine, cysteine or through 
tyrosine molecules (one per monomer on the interior surface). Both 
the interior and exterior surfaces of the capsid shells (devoid of 
RNA) were modified separately, and relaxivity enhancement 
depended upon the local motion of the chelate. The interior surface 
was modified via tyrosine moieties (34, relaxivity per Gd 41.6 mM-
1s-1 and relaxivity per particle 3900 mM-1s-1 at 30 MHz, 25 ºC), 
while the exterior surface was modified via lysine residues 
(relaxivity per Gd 30.7 mM-1s-1 and relaxivity per particle 2500 mM-
1s-1 at 30 MHz, 25 ºC). The rigidity of the linker attaching the 
chelate to the macromolecule clearly affects the relaxivity of the 
complexes, with the more rigid linkers yielding higher 
relaxivities.[95] Furthermore, the interior attachment strategy 
developed in this study has several major advantages that include 
solving solubility issues as well as allowing the development of 
targeted contrast agents via exterior surface modification.  
 
Figure 12. Attachment of HOPO-based contrast agents to an 
aspartate based dendrimer (33) and the internally modified MS2 virus 
capsid (34), (modified tyrosines in the interior are highlighted in green 
on the capsid structure[96]). The linker attaching the Gd chelate to the 
tyrosine is shown in the expanded structure of one of the modified 
tyrosines. 
4. Conclusions 
Detailed studies on lanthanide coordination chemistry have 
yielded exciting possibilities in the production of next-generation 
MRI contrast agents. While the aminocarboxylate-based agents 
currently in use provide some contrast enhancement, there is huge 
room for improvement. New ligand designs may be required to 
attain high relaxivity values at high magnetic field strengths to take 
advantage of the increased resolution made possible by new high-
field instruments. Exploration of the HOPO family of GdIII chelates 
has revealed several promising platforms for consideration as 
practical agents, as shown in the complexes presented herein. These 
complexes possess the unique combination of high hydration 
numbers, fast water exchange rates, high stabilities, and high 
relaxivity values at the fields of interest. Recent work aimed at 
tethering the HOPO compounds to macromolecules is promising, 
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and further optimization of these strategies is ongoing. Regardless of 
the platform used, it is clear that the development of safe, high-
relaxivity MRI contrast agents will remain a challenging task. With 
the multitude of factors that must be considered, agent design and 
evaluation requires a creative, multidisciplinary approach. The 
rewards are great, however, as improved agents would increase the 
breadth of possible MR applications and enhance the power of MRI 
as an imaging modality even further. 
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